Millennium Management LLC Grows Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Millennium Management LLC boosted its position in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 52.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 859,825 shares of the company's stock after purchasing an additional 297,351 shares during the quarter. Millennium Management LLC owned approximately 0.95% of Caribou Biosciences worth $1,367,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Ameriprise Financial Inc. bought a new position in Caribou Biosciences in the fourth quarter worth $649,000. JPMorgan Chase & Co. raised its holdings in Caribou Biosciences by 475.9% in the fourth quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company's stock worth $3,969,000 after purchasing an additional 2,062,563 shares in the last quarter. Barclays PLC raised its holdings in Caribou Biosciences by 12.0% in the fourth quarter. Barclays PLC now owns 145,417 shares of the company's stock worth $231,000 after purchasing an additional 15,578 shares in the last quarter. Northern Trust Corp raised its holdings in Caribou Biosciences by 3.4% in the fourth quarter. Northern Trust Corp now owns 714,737 shares of the company's stock worth $1,136,000 after purchasing an additional 23,531 shares in the last quarter. Finally, Sei Investments Co. bought a new position in Caribou Biosciences in the fourth quarter worth $102,000. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 15.6%

Shares of NASDAQ CRBU traded up $0.17 during trading on Friday, reaching $1.26. The company had a trading volume of 2,027,432 shares, compared to its average volume of 1,401,168. Caribou Biosciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.00. The stock has a market cap of $117.19 million, a PE ratio of -0.76 and a beta of 2.44. The business's 50-day moving average is $0.89 and its 200 day moving average is $1.30.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, hitting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.35 million for the quarter, compared to analysts' expectations of $1.48 million. On average, analysts anticipate that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.